FP Watchlist: Top financial stories for Sept. 22 + MORE Sep 22nd

The “Big Five” Canadian banks offer investment funds and include Royal Bank of Canada, Toronto Dominion Bank (TD Canada Trust), Bank of Nova Scotia, Bank of Montreal and Canadian Imperial Bank of Commerce (CIBC). Let’s explore the best place for you to invest.
Latest News

Are Canadian pension buybacks worth it? Jul 20th

Ask MoneySense I am currently transferring my pension from a provincial to a federal government pension plan. I’m trying to determine if it is worth purchasing the balance of service and, if so, should I use my RRSP or TFSA funds. Here’s some relevant info: Service Credited: 7 years, 140 days.... More »
investment

RRIF and LIF withdrawal rates: Everything you need to know Mar 6th

At some point, a registered retirement savings plan (RRSP) is typically converted to a registered retirement income fund (RRIF). The latest you can defer the conversion of your account is the end of the year you turn 71. This means that by December 31 of your 71st year, you need to either withdraw t.... More »

Federal deficit through first eight months of fiscal year totals $9.1 billion + MORE Jan 27th

OTTAWA _ The federal government’s deficit for the first eight months of the current fiscal year was smaller than a year earlier as revenue growth outpaced increases in spending. According to the latest fiscal monitor, Ottawa rang up a deficit of $9.1 billion for the period from April to Novemb.... More »

Couche-Tard's Q2 earnings up 9% from acquisitions, fuel sales + MORE Nov 27th

The world's second-biggest convenience store operator beat revenue expectations, as the Quebec-based retailer's net earnings rose nine per cent in its most recent quarter thanks in part to acquisitions, improved fuel sales and lower taxes..... More »

National Bank to buy Canadian Western Bank, household wealth jumps to record high and lessons from Swiss Chalet: Must-read business and investing stories - The Globe and Mail Jun 16th

National Bank to buy Canadian Western Bank, household wealth jumps to record high and lessons from Swiss Chalet: Must-read business and investing stories  The Globe and MailView Full Coverage on Google News.... More »
Analysts mixed on whether the Canadian firm landed a good buy, or made a questionable move considering crude prices could remain subdued for years

Continue Reading On theglobeandmail.com »

EDMONTON – A report suggests the number of women who sit on corporate boards in Alberta is less than half the national average, although their presence is slowly increasing.
The study commissioned by the Alberta Securities Commission was done by the University of Calgary’s Haskayne School of Business.
It says women make up 6.6 per cent of corporate board members in the province and 8.9 per cent for companies in Alberta listed on the Toronto Stock Exchange.
An Alberta government website says women’s representation on corporate boards in Canada is 14.5 per cent. Catalyst, a non-profit group, estimates women’s share of board seats on Canadian stock index companies at 21 per cent.
Loren Falkenberg, associate dean of research, said the report aims to shed light on Alberta boardrooms in the hope the data will get corporate leaders to think differently about who they hire.
“I think there is room for more women to serve on boards,” she said Tuesday.
The data reflects the large number of energy, mining and other resource industries in Alberta…

Continue Reading On canadianbusiness.com »

Markets took a hit on Tuesday from falling commodities prices and the widening scandal around Volkswagen’s emissions fiddle.

Continue Reading On cbc.ca »

The Financial Post’s Jonathan Ratner looks at some of the day’s top business and financial stories.

Continue Reading On canoe.ca »

SAN FRANCISCO – The company that sparked an angry backlash after it raised the price of a drug for treating a deadly parasitic infection by more than 5,000 per cent says it will roll back some of the increase.
Turing Pharmaceuticals CEO Martin Shkreli told ABC News on Tuesday that the new price would make Daraprim more accessible, although he did not say what the new price for the drug would be. A spokesman for Turing did not immediately respond to a request for details.
“We’ve agreed to lower the price of Daraprim to a point that is more affordable and is able to allow the company to make a profit, but a very small profit,” Shkreli told ABC.
The company obtained rights to sell the drug, the only U.S.-approved treatment for toxoplasmosis, in August. It hiked the price overnight from $13.50 per pill to $750.
Turing had said it would use profits to improve the drug’s formulation and develop new, better drugs for the infection. It also stressed that some patients can get financial aid from the company to obtain the drug…

Continue Reading On canadianbusiness.com »

Share

PinIt
Compare insurance quotes through Kanetix.ca - save time and money!